Fluency Is Easy. Fidelity Is the Product.
Part of SatelliteAI's content creation suite, the localization pipeline carries content into 23+ languages without losing the one thing both regulators and AI engines actually read: the evidence.
Most translation pipelines optimize for fluency and quietly destroy evidentiary precision. "May indicate" becomes "indicates." "Can help ensure compliance" becomes "ensures compliance." The prose reads beautifully, and the claims are now stronger than the evidence supports — a compliance event in regulated industries and a credibility failure in front of AI engines. SatelliteAI runs two distinct pipelines: translation, which enforces fidelity first and reaches 93–96% evidentiary quality scores in production, and transcreation, which adapts marketing content for cultural resonance while preserving every factual claim. Both feed the same governed review workflow with confidence scores, human review tracking, and automatic stale detection.
Evidentiary fidelity measured on enterprise life sciences content — the hardest category to translate without drift.
| Content Version | Quality Score | Notes |
|---|---|---|
| Enterprise client's existing Korean content | ~45% | Second-generation translation with compounding quality loss |
| SatelliteAI pipeline (first pass) | 87–90% | Rule-based fidelity enforcement |
| SatelliteAI pipeline (production) | 93–96% | Self-critique loop corrected remaining issues |
| Industry average (Korean life sciences) | ~83–86% | Based on comparable content evaluation |
| Industry average (Japanese life sciences) | ~85% | Based on comparable content evaluation |
The 45% number deserves attention. That was real production content at a real enterprise — the result of translating a translation, each generation compounding the drift of the last. Nobody decided to publish content at 45% fidelity. It happened because nobody was measuring.
Second-generation translation chains scored 45% on evidentiary fidelity, compared to 93–96% from a pipeline that prioritizes fidelity over fluency.
The most expensive localization mistake is running the wrong pipeline for the content type.
Preserves meaning, evidence, and structure with fidelity to the source. The claim you published in English is the claim that appears in Korean — same strength, same hedges, same scope.
Adapts content for cultural resonance and market-specific impact. The structure of persuasion is cultural, not linguistic — a landing page that converts in Ohio may fall flat in Osaka.
| Dimension | Translation | Transcreation |
|---|---|---|
| First priority | Source fidelity | Cultural resonance |
| Claims and evidence | Preserved exactly, hedges intact | Preserved factually, framing adapts |
| Structure | Mirrors the source | Free to restructure for the market |
| Brand voice | Carried through terminology controls | Carried through voice profiles per market |
| Best for | Clinical, regulatory, technical, legal | Marketing, landing pages, email, social |
| Change tracking | Fidelity report per pass | Cultural adaptations and creative changes logged |
If a regulator, clinician, or lawyer will ever read it, translate it. If its job is to persuade a specific market, transcreate it. Content that mixes both — a product page with clinical claims and marketing copy — gets transcreated framing around translated claims, with the claims library enforcing the boundary.
Fidelity is engineered, not hoped for. Each pass moves through enforcement, critique, and correction.
The initial translation runs under rule-based fidelity enforcement: hedge preservation is mandatory, quantifier changes are flagged, and claim structure is held to the source. This pass alone reaches 87–90% evidentiary quality — already above industry averages.
Each target language has dominant failure modes, and the pipeline targets them specifically. Korean systematically strips hedges. Japanese reorders information until claim-evidence links weaken. Spanish inflates quantifiers. Chinese obscures claim structure. Generic quality checks miss these because each one produces fluent output.
A second evaluation pass re-reads the translation against the source specifically for evidentiary drift, then corrects what it finds. This loop is what moves production quality from 87–90% to 93–96% — and it is the step most translation pipelines skip entirely.
Every translation and transcreation carries a confidence score into a draft → in review → approved → published workflow with reviewer attribution and timestamps. When the source content changes later, stale detection flags every affected translation automatically — localized content never silently falls out of sync.
The self-critique loop drove production quality from 87–90% to 93–96% by re-reading each translation against its source specifically for evidentiary drift.
AI engines make citation decisions per language. Your English authority does not carry over automatically.
When a user in Munich asks an AI engine a German-market question, the engine retrieves and evaluates German-language content. If your German translation drifted evidentially — hedges stripped, claims restructured, evidence weakened — the engine cites a competitor whose localized content reads as more authoritative, even when your English source page is objectively stronger.
Cross-engine citation verification runs per query in the query's own language, testing whether each engine finds, reads, and cites your localized content through its native search backend. When a translation is the reason you lost the citation, the diagnostic says so — and re-translation with strengthened fidelity controls is the remediation, fed straight back into this pipeline.
For the full multi-market picture — search backends per region, brand portfolios, and market-by-market verification strategy — see AEO for Enterprise.
AI engines evaluate localized content in its own language, so evidentiary drift in translation directly costs citations in that market regardless of source content quality.
For healthcare and other regulated verticals, translation fidelity is a compliance requirement, not a quality preference.
Hedge preservation is mandatory for clinical claims. "May help identify" never becomes "identifies" — the difference between the two is the difference between your evidence and a regulatory finding.
Governed claims from the claims library keep their approval status through translation. A claim approved in English is tracked as the same claim in Japanese — and flagged if the translation altered its strength.
Reviewer attribution, timestamps, and confidence scores on every localized asset, compatible with FDA 21 CFR Part 11 expectations and EU MDR documentation workflows across 23+ languages.
Every market you enter re-tests your content: regulators read the claims, AI engines read the evidence, and customers read the persuasion. A localization pipeline that only measures fluency guarantees you will fail at least one of those readers.
Translate the evidence with fidelity. Transcreate the persuasion for the culture. Measure both. That is the whole discipline.
What ships with the pipeline
Fidelity-first translation, culturally adapted transcreation, and governed review across 23+ languages — connected to the content suite that creates the source and the verification engine that confirms the citations.